Industry
Biotechnology
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.
Loading...
Open
10.31
Mkt cap
663M
Volume
14K
High
10.55
P/E Ratio
-2.85
52-wk high
17.02
Low
10.27
Div yield
N/A
52-wk low
8.75
Portfolio Pulse from Benzinga Newsdesk
April 29, 2024 | 7:57 pm
Portfolio Pulse from Benzinga Newsdesk
April 29, 2024 | 10:22 am
Portfolio Pulse from Benzinga Newsdesk
April 29, 2024 | 9:39 am
Portfolio Pulse from Benzinga Newsdesk
April 11, 2024 | 11:29 am
Portfolio Pulse from Benzinga Insights
April 02, 2024 | 10:25 am
Portfolio Pulse from Benzinga Newsdesk
April 02, 2024 | 8:06 am
Portfolio Pulse from Benzinga Newsdesk
January 24, 2024 | 10:36 am
Portfolio Pulse from Benzinga Newsdesk
November 14, 2023 | 1:11 pm
Portfolio Pulse from Benzinga Newsdesk
November 14, 2023 | 1:09 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.